Analysts See $-0.52 EPS for Spring Bank Pharmaceuticals, Inc. (SBPH)

April 16, 2018 - By reb123z

Analysts expect Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) to report $-0.52 EPS on April, 27.They anticipate $0.05 EPS change or 10.64 % from last quarter’s $-0.47 EPS. After having $-0.47 EPS previously, Spring Bank Pharmaceuticals, Inc.’s analysts see 10.64 % EPS growth. The stock decreased 3.36% or $0.47 during the last trading session, reaching $13.52. About 15,438 shares traded. Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) has risen 64.52% since April 17, 2017 and is uptrending. It has outperformed by 52.97% the S&P500.

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid chemistry platform. The company has market cap of $175.27 million. The Company’s SMNH compounds are small divisions of nucleic acids that the firm creates to target and modulate the activity of specific proteins implicated in various disease states. It currently has negative earnings. The company's lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus.

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.